Ranbaxy Farmaceutica Ltda : Pharmaceutical Import Profile — Brazil (DGFT 2022–2026)

Name: Ranbaxy Farmaceutica Ltda : Pharmaceutical Import Records from India — 3 Products, $5.8M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ranbaxy Farmaceutica Ltda : — Pharmaceutical Importer Profile (2026) | 3 Products, $5.8M Trade | TransData Nexus

Ranbaxy Farmaceutica Ltda :

Pharmaceutical Importer · Brazil · Advanced Diabetes Medications Focus · $5.8M Total Trade · DGFT Verified

Ranbaxy Farmaceutica Ltda : is a pharmaceutical importer based in Brazil with a total trade value of $5.8M across 3 products in 3 therapeutic categories. Based on 146 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ranbaxy Farmaceutica Ltda : sources from 1 verified Indian supplier, with Sun Pharmaceutical Industries Limited accounting for 100.0% of imports.

Ranbaxy Farmaceutica Ltda : — Import Portfolio & Supplier Network

Ranbaxy Farmaceutica Ltda : import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ranbaxy Farmaceutica Ltda :?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sun Pharmaceutical Industries Limited	$42.3M	1,395	100.0%

Ranbaxy Farmaceutica Ltda : sources from 1 verified Indian supplier across 787 distinct formulations. The sourcing is highly concentrated — Sun Pharmaceutical Industries Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Nortriptyline hydrochloride capsules	$895.5K	22
Sertraline hcl TAB 50MG Pack:box100x10s	$804.5K	17
Clopidogrel bisulphate TAB 75MG	$570.6K	13
Amiodarone TAB 200MG 50x10s braz	$568.6K	13
Nortriptyline hydrochloride capsules	$535.3K	11
Citalopram TAB 20MG Pack:box30s	$500.0K	10
Sertraline hcl TAB 50MG Pack:box50x10s	$496.7K	16
Cinnarizine tablets 75MG Pack:box3x10s	$469.9K	10
Isotretinoin cap 20 MG Pack:box50x10s	$400.0K	8
Gliclazide TAB 60 MG 50x10b	$392.5K	8
Nortriptyline cap 50MG Pack:box3x10s	$388.6K	8
Gliclazide rxy TAB 30MG 50x10b Each contains: gliclazide modified release tablets 30 MG : Pack : box50x10s	$381.4K	10
Clopidogrel bisulphate TAB 75MG	$379.9K	8
Oxcarbazepine tablets 300 MG Pack:box60s	$350.0K	7
Citalopram TAB 20MG Pack:box30s	$350.0K	7

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Gliclazide	Advanced Diabetes Medications	$2.3M	76	0.8%	9
2	Magnesium	Vitamins & Supplements	$1.9M	37	0.5%	16
3	Sodium	Nutritional Supplements	$1.6M	33	0.5%	7

Ranbaxy Farmaceutica Ltda : imports 3 pharmaceutical products across 3 categories into Brazil totaling $5.8M.

Ranbaxy Farmaceutica Ltda : — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ranbaxy Farmaceutica Ltda. is a Brazilian pharmaceutical company specializing in the wholesale distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established on November 4, 1993, the company is headquartered in Rio de Janeiro, Brazil. It operates under the legal structure of a Sociedade Empresária Limitada (Limited Liability Company), with a capital social of R$ 17,366,914.00.

The company's primary activity is the wholesale distribution of human-use pharmaceuticals, as classified under the CNAE code 46.44-3/01. Ranbaxy Farmaceutica Ltda. has expanded its operations with additional facilities in Barueri, São Paulo, and Goiânia, Goiás, indicating a strategic approach to enhance its distribution capabilities across Brazil. (econodata.com.br)

2Distribution Network

Ranbaxy Farmaceutica Ltda. has established a robust distribution network with multiple facilities across Brazil. The main office is located at Rua Francisco de Souza Melo, 252, Cordovil, Rio de Janeiro, RJ, 21.010-410. Additional facilities include a branch in Barueri, São Paulo, situated at Alameda Tocantins, 125, Alphaville Industrial, and another in Goiânia, Goiás, at Avenida Doutor Napoleão R. Laureano, 2821, Fazenda Planície. (econodata.com.br)

These strategically located warehouses enable Ranbaxy Farmaceutica Ltda. to effectively manage logistics and ensure timely delivery of pharmaceutical products throughout Brazil. The company's distribution network is designed to support its extensive import operations, facilitating the efficient movement of goods from suppliers to end-users across the country.

3Industry Role

Ranbaxy Farmaceutica Ltda. plays a significant role in Brazil's pharmaceutical supply chain as a primary wholesaler. The company imports a diverse range of finished pharmaceutical formulations from India, including advanced diabetes medications, vitamins, and nutritional supplements. By sourcing these products, Ranbaxy Farmaceutica Ltda. contributes to the availability of essential medications in the Brazilian market, catering to various therapeutic needs.

The company's operations are characterized by a high degree of supplier concentration, primarily importing from a single supplier, SUN PHARMACEUTICAL INDUSTRIES LIMITED. This sourcing strategy underscores Ranbaxy Farmaceutica Ltda.'s reliance on established partnerships to meet the pharmaceutical demands of the Brazilian market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ranbaxy Farmaceutica Ltda :

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ranbaxy Farmaceutica Ltda.'s sourcing strategy exhibits a high degree of concentration, with 100% of its pharmaceutical imports originating from SUN PHARMACEUTICAL INDUSTRIES LIMITED. This exclusive partnership indicates a strategic choice to maintain a streamlined supply chain and potentially negotiate favorable terms.

However, such dependency on a single supplier introduces risks related to supply chain disruptions, price fluctuations, and potential regulatory changes affecting the supplier. The stability of this relationship is crucial for Ranbaxy Farmaceutica Ltda.'s operations, and any challenges faced by SUN PHARMACEUTICAL INDUSTRIES LIMITED could directly impact the company's ability to meet market demands.

2Supply Chain Resilience

The resilience of Ranbaxy Farmaceutica Ltda.'s supply chain is closely tied to the stability and reliability of SUN PHARMACEUTICAL INDUSTRIES LIMITED. Given the exclusive nature of this partnership, the company may face challenges in diversifying its supplier base. The absence of backup suppliers could pose risks in the event of supply chain disruptions, such as production delays or logistical issues.

Additionally, the company's focus on a limited range of formulations, with 787 unique formulations imported, suggests a specialized product portfolio. While this specialization can enhance operational efficiency, it may also limit flexibility in adapting to changing market demands or regulatory requirements.

Importing Pharmaceuticals into Brazil — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Brazil

1Regulatory Authority & Framework

In Brazil, the regulation of pharmaceutical products is overseen by the Agência Nacional de Vigilância Sanitária (ANVISA), the National Health Surveillance Agency. ANVISA is responsible for ensuring the safety, efficacy, and quality of health-related products, including pharmaceuticals. (gov.br)

Key legislation governing pharmaceutical imports includes Law No. 9,782/1999, which established ANVISA, and Law No. 6,360/1976, which regulates the manufacture and marketing of pharmaceutical products. These laws outline the requirements for product registration, importation, and distribution within Brazil.

2Import Licensing & GMP

Import licensing in Brazil requires that pharmaceutical products be registered with ANVISA before they can be marketed. This process involves submitting detailed documentation, including evidence of Good Manufacturing Practice (GMP) compliance. ANVISA recognizes GMP certifications from various international standards, such as EU GMP, WHO GMP, and PIC/S, facilitating the importation of products manufactured under these guidelines. (gov.br)

Wholesalers like Ranbaxy Farmaceutica Ltda. must obtain authorization from ANVISA to distribute pharmaceutical products. This authorization ensures that the company adheres to regulatory standards concerning storage, handling, and distribution, maintaining the integrity and safety of the pharmaceutical supply chain.

Ranbaxy Farmaceutica Ltda : — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ranbaxy Farmaceutica Ltda.'s focus on advanced diabetes medications, vitamins, and nutritional supplements aligns with the growing demand for chronic disease management and preventive healthcare in Brazil. The prevalence of diabetes and other lifestyle-related conditions has increased, driving the need for effective therapeutic options.

The company's import strategy reflects an understanding of market needs, positioning itself to provide essential medications that address prevalent health issues. By sourcing these products from India, Ranbaxy Farmaceutica Ltda. leverages cost-effective manufacturing while meeting the therapeutic demands of the Brazilian population.

2Sourcing Profile

Ranbaxy Farmaceutica Ltda. employs a sourcing strategy that emphasizes the importation of generic drugs, focusing on finished pharmaceutical formulations. This approach allows the company to offer affordable therapeutic options to the Brazilian market. The preference for formulations that address chronic conditions, such as diabetes, indicates a strategic alignment with prevalent health concerns.

India's established pharmaceutical manufacturing capabilities and adherence to international GMP standards make it a suitable partner for Ranbaxy Farmaceutica Ltda.'s procurement needs. The company's sourcing profile reflects a commitment to quality, affordability, and responsiveness to market demands.

Market Positioning

Seller's Guide — How to Become a Supplier to Ranbaxy Farmaceutica Ltda :

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Ranbaxy Farmaceutica Ltda. by offering complementary products that align with the company's existing portfolio. Introducing innovative formulations or addressing unmet therapeutic needs could enhance the company's product offerings and market competitiveness.

Identifying gaps in Ranbaxy Farmaceutica Ltda.'s current sourcing, such as the need for additional suppliers to mitigate risks associated with single-source dependency, presents an opportunity for Indian exporters to establish partnerships and diversify the company's

TransData Nexus Research · Industry procurement practicesMar 2026

Frequently Asked Questions — Ranbaxy Farmaceutica Ltda :

What products does Ranbaxy Farmaceutica Ltda : import from India?

Ranbaxy Farmaceutica Ltda : imports 3 pharmaceutical products across 3 categories. Top imports: Gliclazide ($2.3M), Magnesium ($1.9M), Sodium ($1.6M).

Who supplies pharmaceuticals to Ranbaxy Farmaceutica Ltda : from India?

Ranbaxy Farmaceutica Ltda : sources from 1 verified Indian suppliers. The primary supplier is Sun Pharmaceutical Industries Limited (100.0% of imports, $42.3M).

What is Ranbaxy Farmaceutica Ltda :'s total pharmaceutical import value?

Ranbaxy Farmaceutica Ltda :'s total pharmaceutical import value from India is $5.8M, based on 146 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ranbaxy Farmaceutica Ltda : focus on?

Ranbaxy Farmaceutica Ltda : imports across 3 categories. The largest: Advanced Diabetes Medications (39.3%), Vitamins & Supplements (32.1%), Nutritional Supplements (28.6%).

Get Full Ranbaxy Farmaceutica Ltda : Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.